Patients with advanced and metastatic renal cell carcinoma
treated with targeted therapy in the Czech Republic: twenty
cancer centres, six agents, one database

J 2012

Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database

POPRACH, Alexandr; Zbyněk BORTLÍČEK; Tomáš BÜCHLER; Bohuslav MELICHAR; Radek LAKOMÝ et al.

Základní údaje

Originální název

Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database

Autoři

POPRACH, Alexandr; Zbyněk BORTLÍČEK; Tomáš BÜCHLER; Bohuslav MELICHAR; Radek LAKOMÝ; Rostislav VYZULA; Petr BRABEC; Marek SVOBODA; Ladislav DUŠEK a Jakub GREGOR

Vydání

Medical Oncology, 2012, 1357-0560

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.147

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/12:00062394

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1007/s12032-012-0286-9

UT WoS

000311513800045

Klíčová slova anglicky

kidney cancer; renal carcinoma; epidemiology; incidence

Změněno: 23. 4. 2013 00:18, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

The incidence and mortality of renal cell carcinoma (RCC) in the Czech Republic are among the highest in the world. Several targeted agents have been recently approved for the treatment of advanced/metastatic RCC. Objective: Presentation of a national clinical database for monitoring and assessment of patients with advanced/metastatic RCC treated with targeted therapy. The RenIS (RENal Information System, http://renis.registry.cz) registry is a noninterventional post-registration database of epidemiological and clinical data of patients with RCC treated with targeted therapies in the Czech Republic. Twenty cancer centres eligible for targeted therapy administration participate in the project. As of November 2011, six agents were approved and reimbursed from public health insurance, including bevacizumab, everolimus, pazopanib, sorafenib, sunitinib, and temsirolimus. As of 10 October 2011, 1,541 patients with valid recordswere entered into the database.Comparison with population-based data from the Czech National Cancer Registry revealed that RCC patients treated with targeted therapy are significantly younger (median age at diagnosis 59 vs. 66 years). Most RenIS registry patients were treated with sorafenib and sunitinib, many patients sequentially with both agents. Over 10 % of patients were also treated with everolimus in the second or third line. Progression-free survival times achieved were comparable to phase III clinical trials. The RenIS registry has become an important tool and source of information for the management of cancer care and clinical practice, providing comprehensive data onmonitoring and assessment of RCC targeted therapy on a national level.

Citovat

POPRACH, Alexandr; Zbyněk BORTLÍČEK; Tomáš BÜCHLER; Bohuslav MELICHAR; Radek LAKOMÝ; Rostislav VYZULA; Petr BRABEC; Marek SVOBODA; Ladislav DUŠEK a Jakub GREGOR. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database. Medical Oncology. 2012, roč. 29, č. 5, s. 3314-3320. ISSN 1357-0560. Dostupné z: https://doi.org/10.1007/s12032-012-0286-9.

@article{1078919,
   author = {Poprach, Alexandr and Bortlíček, Zbyněk and Büchler, Tomáš and Melichar, Bohuslav and Lakomý, Radek and Vyzula, Rostislav and Brabec, Petr and Svoboda, Marek and Dušek, Ladislav and Gregor, Jakub},
   article_number = {5},
   doi = {https://doi.org/10.1007/s12032-012-0286-9},
   keywords = {kidney cancer; renal carcinoma; epidemiology; incidence},
   language = {eng},
   issn = {1357-0560},
   journal = {Medical Oncology},
   title = {Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database},
   volume = {29},
   year = {2012}
}

TY  - JOUR
ID  - 1078919
AU  - Poprach, Alexandr - Bortlíček, Zbyněk - Büchler, Tomáš - Melichar, Bohuslav - Lakomý, Radek - Vyzula, Rostislav - Brabec, Petr - Svoboda, Marek - Dušek, Ladislav - Gregor, Jakub
PY  - 2012
TI  - Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database
JF  - Medical Oncology
VL  - 29
IS  - 5
SP  - 3314-3320
EP  - 3314-3320
SN  - 13570560
KW  - kidney cancer
KW  - renal carcinoma
KW  - epidemiology
KW  - incidence
N2  - The incidence and mortality of renal cell carcinoma (RCC) in the Czech Republic are among the highest in the world. Several targeted agents have been recently approved for the treatment of advanced/metastatic RCC. Objective: Presentation of a national clinical database for monitoring and assessment of patients with advanced/metastatic RCC treated with targeted therapy. The RenIS (RENal Information System, http://renis.registry.cz) registry is a noninterventional post-registration database of epidemiological and clinical data of patients with RCC treated with targeted therapies in the Czech Republic. Twenty cancer centres eligible for targeted therapy administration participate in the project. As of November 2011, six agents were approved and reimbursed from public health insurance, including bevacizumab, everolimus, pazopanib, sorafenib, sunitinib, and temsirolimus. As of 10 October 2011, 1,541 patients with valid recordswere entered into the database.Comparison with population-based data from the Czech National Cancer Registry revealed that RCC patients treated with targeted therapy are significantly younger (median age at diagnosis 59 vs. 66 years). Most RenIS registry patients were treated with sorafenib and sunitinib, many patients sequentially with both agents. Over 10 % of patients were also treated with everolimus in the second or third line. Progression-free survival times achieved were comparable to phase III clinical trials. The RenIS registry has become an important tool and source of information for the management of cancer care and clinical practice, providing comprehensive data onmonitoring and assessment of RCC targeted therapy on a national level.
ER  -

POPRACH, Alexandr; Zbyněk BORTLÍČEK; Tomáš BÜCHLER; Bohuslav MELICHAR; Radek LAKOMÝ; Rostislav VYZULA; Petr BRABEC; Marek SVOBODA; Ladislav DUŠEK a Jakub GREGOR. Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database. \textit{Medical Oncology}. 2012, roč.~29, č.~5, s.~3314-3320. ISSN~1357-0560. Dostupné z: https://doi.org/10.1007/s12032-012-0286-9.

Přehled o publikaci